MUTYH

Summary

MUTYH (mutY DNA glycosylase, HGNC:7527) is a protein-coding gene on chromosome 1p34.1, encoding Adenine DNA glycosylase (Q9UIF7). Involved in oxidative DNA damage repair.

This gene encodes a DNA glycosylase involved in oxidative DNA damage repair. The enzyme excises adenine bases from the DNA backbone at sites where adenine is inappropriately paired with guanine, cytosine, or 8-oxo-7,8-dihydroguanine, a major oxidatively damaged DNA lesion. The protein is localized to the nucleus and mitochondria. This gene product is thought to play a role in signaling apoptosis by the introduction of single-strand breaks following oxidative damage. Mutations in this gene result in heritable predisposition to colorectal cancer, termed MUTYH-associated polyposis (MAP). Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 4595 — RefSeq curated summary.

At a glance

• Gene–disease (curated): familial adenomatous polyposis 2 (Definitive, ClinGen) — +3 more curated relationships
• GWAS associations: 2
• Clinical variants (ClinVar): 4,186 total — 184 pathogenic, 150 likely-pathogenic
• Phenotypes (HPO): 64
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_001048174

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7527
Approved symbol	MUTYH
Name	mutY DNA glycosylase
Location	1p34.1
Locus type	gene with protein product
Status	Approved
Aliases	MYH
Ensembl gene	ENSG00000132781
Ensembl biotype	protein_coding
OMIM	604933
Entrez	4595

Gene structure

Transcript identifiers

Ensembl transcripts: 110 — 80 protein_coding, 15 nonsense_mediated_decay, 13 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000354383, ENST00000355498, ENST00000372098, ENST00000372104, ENST00000372110, ENST00000372115, ENST00000412971, ENST00000435155, ENST00000448481, ENST00000450313, ENST00000456914, ENST00000461495, ENST00000462387, ENST00000462388, ENST00000466231, ENST00000467459, ENST00000467940, ENST00000470256, ENST00000474703, ENST00000475516, ENST00000476789, ENST00000478796, ENST00000479746, ENST00000481139, ENST00000481571, ENST00000482094, ENST00000483127, ENST00000483642, ENST00000485271, ENST00000485484, ENST00000488731, ENST00000492494, ENST00000525160, ENST00000528013, ENST00000529892, ENST00000529984, ENST00000531105, ENST00000533178, ENST00000534453, ENST00000671856, ENST00000672011, ENST00000672314, ENST00000672593, ENST00000672764, ENST00000672818, ENST00000673134, ENST00000674679, ENST00000710952, ENST00000713749, ENST00000713750, ENST00000713751, ENST00000873954, ENST00000873955, ENST00000873956, ENST00000873957, ENST00000873958, ENST00000873959, ENST00000873960, ENST00000873961, ENST00000873962, ENST00000873963, ENST00000873964, ENST00000873965, ENST00000873966, ENST00000873967, ENST00000873968, ENST00000873969, ENST00000873970, ENST00000938227, ENST00000938228, ENST00000938229, ENST00000938230, ENST00000938231, ENST00000938232, ENST00000938233, ENST00000938234, ENST00000938235, ENST00000938236, ENST00000938237, ENST00000938238, ENST00000938239, ENST00000938240, ENST00000938241, ENST00000938242, ENST00000938243, ENST00000938244, ENST00000938245, ENST00000938246, ENST00000938247, ENST00000946255, ENST00000946256, ENST00000946257, ENST00000946258, ENST00000946259, ENST00000946260, ENST00000946261, ENST00000946262, ENST00000946263, ENST00000946264, ENST00000946265, ENST00000946266, ENST00000946267, ENST00000946268, ENST00000946269, ENST00000946270, ENST00000946271, ENST00000946272, ENST00000946273, ENST00000946274, ENST00000946275

RefSeq mRNA: 32 — MANE Select: NM_001048174 NM_001048171, NM_001048172, NM_001048173, NM_001048174, NM_001128425, NM_001293190, NM_001293191, NM_001293192, NM_001293195, NM_001293196, NM_001350650, NM_001350651, NM_001407069, NM_001407070, NM_001407071, NM_001407072, NM_001407073, NM_001407075, NM_001407077, NM_001407078, NM_001407079, NM_001407080, NM_001407081, NM_001407082, NM_001407083, NM_001407085, NM_001407086, NM_001407087, NM_001407088, NM_001407089, NM_001407091, NM_012222

CCDS: CCDS41321, CCDS41322, CCDS520, CCDS72776, CCDS72777, CCDS90938

Canonical transcript exons

ENST00000456914 — 16 exons

Exon	Start	End
ENSE00001787263	45339899	45339970
ENSE00003461605	45333097	45333170
ENSE00003511189	45330516	45330557
ENSE00003520371	45329242	45329437
ENSE00003522055	45332918	45332959
ENSE00003546541	45333285	45333324
ENSE00003548680	45332166	45332310
ENSE00003570172	45331420	45331556
ENSE00003583391	45331661	45331849
ENSE00003651673	45331182	45331334
ENSE00003664970	45332023	45332086
ENSE00003665238	45332574	45332687
ENSE00003673115	45332763	45332834
ENSE00003702886	45332391	45332488
ENSE00003786928	45333413	45333561
ENSE00004282775	45334391	45334511

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 95.55.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.3079 / max 73.7436, expressed in 1755 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12115	4.0389	1471
12112	3.3826	1410
12113	1.6522	905
12114	0.2341	109

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar hemisphere	UBERON:0002245	95.55	gold quality
cerebellar cortex	UBERON:0002129	95.53	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.51	gold quality
cerebellum	UBERON:0002037	95.49	gold quality
mucosa of transverse colon	UBERON:0004991	93.00	gold quality
granulocyte	CL:0000094	91.94	gold quality
right lobe of thyroid gland	UBERON:0001119	91.90	gold quality
right uterine tube	UBERON:0001302	91.56	gold quality
left lobe of thyroid gland	UBERON:0001120	91.31	gold quality
thyroid gland	UBERON:0002046	91.14	gold quality
spleen	UBERON:0002106	91.02	gold quality
tibial nerve	UBERON:0001323	90.78	gold quality
pituitary gland	UBERON:0000007	90.65	gold quality
left ovary	UBERON:0002119	90.55	gold quality
endocervix	UBERON:0000458	90.52	gold quality
right ovary	UBERON:0002118	90.08	gold quality
adenohypophysis	UBERON:0002196	90.05	gold quality
ectocervix	UBERON:0012249	90.00	gold quality
ovary	UBERON:0000992	89.80	gold quality
metanephros cortex	UBERON:0010533	89.67	gold quality
body of uterus	UBERON:0009853	89.63	gold quality
transverse colon	UBERON:0001157	89.52	gold quality
uterine cervix	UBERON:0000002	89.49	gold quality
prostate gland	UBERON:0002367	89.31	gold quality
small intestine Peyer’s patch	UBERON:0003454	89.31	gold quality
lower esophagus mucosa	UBERON:0035834	89.13	gold quality
cortex of kidney	UBERON:0001225	88.98	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	88.95	gold quality
small intestine	UBERON:0002108	88.61	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.46	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.20
E-MTAB-7249	no	21.68

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MEF2A

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• interaction with mismatch repair proteins MutS homolog 2/MutS homolog 6 (PMID:11801590)
• Functional interaction of MutY homolog with proliferating cell nuclear antigen in fission yeast (and in human) (PMID:11805113)
• effect of a single nucleotide polymorphism (SNP) in the MYH gene on the difference in the expression levels of its products (PMID:12056405)
• Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C–>T:A mutations (PMID:12393807)
• Germline mutations but not somatic changes at this locus contribute to the pathogenesis of unselected colorectal cancers. (PMID:12707038)
• OGG1 and MYH function as suppressors for G:C to T:A transversions by 8OHG but not by BPDE in human cells. (PMID:12807753)
• MutY phosphorylation is defective in human colorectal cancer cell lines with wild-type MutY alleles (PMID:12966098)
• Biallelic MYH mutations confer susceptibility to colorectal cancer (PMID:14991577)
• MYH-associated polyposis(MAP) is present in about 20% of Italian FAP/AAPC patients, and in some patients with colorectal adenomas in the general population. Mutation 1395delGGA is a subpolymorphic MYH mutational event in some Caucasian populations. (PMID:14999774)
• Transversions in KRAS2 or APC are more common in colorectal cancers with single germ-line MYH variants than colorectal cancers with wild-type MYH. (PMID:15034862)
• patients with MYH-associated adenomatous polyposis were either apparently sporadic cases or had a family history consistent with recessive inheritance (PMID:15188161)
• data suggest that somatic mutations of base excision repair gene MYH contribute to the development of a sub-set of sporadic gastric cancers (PMID:15273732)
• MYH mutations cause multiple adenomas of the GI tract and seem to act by increasing the frequency of somatic APC mutations. (PMID:15290654)
• 3 new mutations (c.340T>C [p.Y114H]; c.503G>A [p.R168H]; and c.1186_1187insGG [p.E396fsX437]) are described. (PMID:15366000)
• Increased expression of the DNA glycosylase repair enzyme hMYH in A549 cells exposed to O2 and IR leads to improvements in cell survival. (PMID:15450125)
• Loss of heterozygosity in at least one of four loci in MYH was detected in eight (47%) of 17 colorectal tumors from monoallelic MYH gene mutation carriers but in only two (20%) of 10 colorectal tumors from biallelic MYH gene mutation carriers. (PMID:15523092)
• Mutation spectrum for MYH by direct DNA sequencing in 219 anonymous North Americans in genetic testing for polyposis colorectal cancer. (PMID:15635083)
• Pathogenic mechanisms underlying two hMYH polyposis-associated mutations. (PMID:15673720)
• Germ-line mutations of the MYH gene were studied in Japanese patients with multiple colorectal adenomas. (PMID:15890374)
• These data provide the strongest evidence to date for a causative role of BER defects in colorectal cancer etiology and show, to our knowledge for the first time, that heterozygous MUTYH mutations predispose to colorectal cancer later in life. (PMID:15931596)
• normal role of MutYH in the base excision repair of adenines misincorporated opposite 7,8-dihydro-8-oxoguanine in familial adenomatous polyposis (PMID:16042573)
• there was no significant difference in MYH mutation carrier status between patients with hepatocellular carcinoma, cholangiocarcinoma, and non-cancerous controls (PMID:16292541)
• Results warrant further study to test the hypothesis of mutations in MMR genes (in particular MSH6) and MUTYH acting together to increase cancer risk. (PMID:16408224)
• Mutation in MYH may be rarely involved in the pathogenesis of multiple sporadic colorectal adenomas in Korean population. (PMID:16521226)
• biallelic MUTYH mutations are the underlying genetic basis in a substantial fraction of patients with adenomatous polyposis (PMID:16557584)
• Our results suggest that hMUTYH might be a useful marker of oxidative stress and that oxidative stress and genomic instability are important in the PD disease process. (PMID:16773329)
• low-penetrance alleles of MYH are enriched in MMR gene mutation-negative colon cancer families (PMID:16774938)
• Mutations in the MUTYH gene have been reported to be associated with increased risk of developing colorectal cancer. This study underscores the need for large sample sizes in order to identify small gene effects when the disease allele frequency is low. (PMID:16804517)
• Mutations in MBD4 are unlikely to be implicated in HPS; MYH mutations should be studied, especially when adenomas occur in the same patient. (PMID:16831587)
• Patients with biallelic MYH mutations showed disappearance of staining from the nucleus, and segregation of immunoreactivity in the cytoplasm, both in neoplastic and surrounding healthy mucosa. (PMID:16890597)
• Colorectal cancer has an important genetic component. Colorectal polyposis associated with mutations in the MYH gene is an autosomal recessive syndrome characterized by the development of colorectal adenomas and cancer. (PMID:16938257)
• Results show high frequency of MUTYH mutations in patients with multiple polyposis. (PMID:16941501)
• Biallelic germline mutation of MYH in colorectal cancer also demonstrated microsatellite instability as a result of biallelic hypermethylation of the MLH1 promoter. (PMID:17031395)
• MSH6/MUTYH heterozygote mutation carriers display a predominant HNPCC molecular tumour phenotype, with microsatellite instability and underrepresentation of G>T transversions. (PMID:17039270)
• characterization of one newly identified MYH-associated polyposis MYH missense mutation (R231L) that lies adjacent to the putative hMSH6 binding domain; the mutant protein has severe defects in A/GO binding & adenine glycosylase activities (PMID:17081686)
• MYH mutations are unlikely to contribute to prostate cancer risk. (PMID:17219200)
• germline MYH mutations (by dHPLCO) in 20 clinic-based multiple adenoma patients who were adenomatous polyposis coli (APC) mutation-negative. (PMID:17219385)
• Two novel mutations of MYH and a novel OGG1 polymorphism seemed to be associated with multiple colorectal adenomas in Korean families. (PMID:17252231)
• the presence of germline mutations in the MUTYH genes in attenuated familial adenomatous polyposis. (PMID:17489848)
• No germline mutations in MUTYH in Multiple colorectal adenoma. (PMID:17505512)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mutyh	ENSDARG00000074889
mus_musculus	Mutyh	ENSMUSG00000028687
rattus_norvegicus	Mutyh	ENSRNOG00000017887

Paralogs (1): NTHL1 (ENSG00000065057)

Protein

Protein identifiers

Adenine DNA glycosylase — Q9UIF7 (reviewed: Q9UIF7)

Alternative names: MutY homolog

All UniProt accessions (25): Q9UIF7, A0A5F9ZHI2, A0A5F9ZI14, A0A5F9ZI60, A0A6Q8PF38, A0AAQ5BGW7, E5KP25, E5KP26, E5KP27, E5KP28, E9PI11, E9PIW5, E9PKM9, E9PLT4, E9PM53, E9PMH1, E9PNY0, E9PP30, E9PP34, H0YCA8, H0YCY5, H0YEI2, H0YER6, Q5T413, Q5T418

UniProt curated annotations — full annotation on UniProt →

Function. Involved in oxidative DNA damage repair. Initiates repair of AoxoG to CG by removing the inappropriately paired adenine base from the DNA backbone. Possesses both adenine and 2-OH-A DNA glycosylase activities.

Subcellular location. Nucleus. Mitochondrion.

Disease relevance. Familial adenomatous polyposis 2 (FAP2) [MIM:608456] A condition characterized by the development of multiple colorectal adenomatous polyps, benign neoplasms derived from glandular epithelium. Some affected individuals may develop colorectal carcinoma. The disease is caused by variants affecting the gene represented in this entry. Gastric cancer (GASC) [MIM:613659] A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. The gene represented in this entry may be involved in disease pathogenesis. Somatic mutations contribute to the development of a sub-set of sporadic gastric cancers in carriers of Helicobacter pylori.

Cofactor. Binds 1 [4Fe-4S] cluster. The cluster does not appear to play a role in catalysis, but is probably involved in the proper positioning of the enzyme along the DNA strand.

Similarity. Belongs to the Nth/MutY family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q9UIF7-1	Alpha-1	yes
Q9UIF7-2	Alpha-2
Q9UIF7-3	Alpha-3
Q9UIF7-4	Beta-1
Q9UIF7-5	Gamma-2
Q9UIF7-6	Gamma-3

RefSeq proteins (32): NP_001041636, NP_001041637, NP_001041638, NP_001041639, NP_001121897, NP_001280119, NP_001280120, NP_001280121, NP_001280124, NP_001280125, NP_001337579, NP_001337580, NP_001393998, NP_001393999, NP_001394000, NP_001394001, NP_001394002, NP_001394004, NP_001394006, NP_001394007, NP_001394008, NP_001394009, NP_001394010, NP_001394011, NP_001394012, NP_001394014, NP_001394015, NP_001394016, NP_001394017, NP_001394018, NP_001394020, NP_036354 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000086	NUDIX_hydrolase_dom	Domain
IPR000445	HhH_motif	Conserved_site
IPR003265	HhH-GPD_domain	Domain
IPR003651	Endonuclease3_FeS-loop_motif	Conserved_site
IPR004035	Endouclease-III_FeS-bd_BS	Binding_site
IPR004036	Endonuclease-III-like_CS2	Conserved_site
IPR011257	DNA_glycosylase	Homologous_superfamily
IPR015797	NUDIX_hydrolase-like_dom_sf	Homologous_superfamily
IPR023170	HhH_base_excis_C	Homologous_superfamily
IPR029119	MutY_C	Domain
IPR044298	MIG/MutY	Family

Pfam: PF00633, PF00730, PF14815

UniProt features (110 total): sequence variant 60, helix 22, strand 11, binding site 4, splice variant 3, turn 2, mutagenesis site 2, chain 1, domain 1, region of interest 1, short sequence motif 1, active site 1, site 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
8FAY	X-RAY DIFFRACTION	1.91
3N5N	X-RAY DIFFRACTION	2.3
1X51	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UIF7-F1	79.62	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 131 (proton donor/acceptor); 233 (transition state stabilizer)

Ligand- & substrate-binding residues (4): 287; 294; 297; 303

Mutagenesis-validated functional residues (2):

Position	Phenotype
121	does not affect dna glycosylase activity. does not affect function in dna repair.
233	loss of dna glycosylase activity.

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-110330	Recognition and association of DNA glycosylase with site containing an affected purine
R-HSA-110331	Cleavage of the damaged purine
R-HSA-110357	Displacement of DNA glycosylase by APEX1
R-HSA-9608287	Defective MUTYH substrate binding
R-HSA-9608290	Defective MUTYH substrate processing

MSigDB gene sets: 297 (showing top): MORF_ATRX, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, KAUFFMANN_DNA_REPAIR_GENES, MUELLER_PLURINET, GOBP_DNA_MODIFICATION, MORF_PPP5C, BLALOCK_ALZHEIMERS_DISEASE_UP, chr1p34, GOBP_DNA_DAMAGE_RESPONSE, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, GOBP_MISMATCH_REPAIR, FISCHER_DREAM_TARGETS, REACTOME_DNA_REPAIR, MODULE_568

GO Biological Process (7): DNA repair (GO:0006281), base-excision repair (GO:0006284), mismatch repair (GO:0006298), depurination (GO:0045007), negative regulation of necroptotic process (GO:0060546), response to stress (GO:0006950), DNA damage response (GO:0006974)

GO Molecular Function (14): purine-specific mismatch base pair DNA N-glycosylase activity (GO:0000701), DNA N-glycosylase activity (GO:0019104), oxidized purine DNA binding (GO:0032357), MutSalpha complex binding (GO:0032407), 8-oxo-7,8-dihydroguanine DNA N-glycosylase activity (GO:0034039), adenine/guanine mispair binding (GO:0035485), metal ion binding (GO:0046872), 4 iron, 4 sulfur cluster binding (GO:0051539), DNA binding (GO:0003677), catalytic activity (GO:0003824), protein binding (GO:0005515), hydrolase activity (GO:0016787), hydrolase activity, acting on glycosyl bonds (GO:0016798), iron-sulfur cluster binding (GO:0051536)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), mitochondrion (GO:0005739)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Depurination	2
Defective Base Excision Repair Associated with MUTYH	2
Resolution of Abasic Sites (AP sites)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA repair	2
intracellular membrane-bounded organelle	2
DNA metabolic process	1
DNA damage response	1
base-excision repair, AP site formation	1
DNA modification	1
regulation of necroptotic process	1
negative regulation of programmed necrotic cell death	1
necroptotic process	1
response to stimulus	1
cellular response to stress	1
mismatch base pair DNA N-glycosylase activity	1
hydrolase activity, hydrolyzing N-glycosyl compounds	1
catalytic activity, acting on DNA	1
oxidized DNA binding	1
mismatch repair complex binding	1
oxidized purine nucleobase lesion DNA N-glycosylase activity	1
mismatched DNA binding	1
cation binding	1
iron-sulfur cluster binding	1
nucleic acid binding	1
molecular_function	1
binding	1
catalytic activity	1
hydrolase activity	1
metal cluster binding	1
nuclear lumen	1
cellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

1726 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MUTYH	MSH6	P52701	976
MUTYH	OGG1	P78554	971
MUTYH	NUDT1	P36639	927
MUTYH	MLH1	P40692	914
MUTYH	PMS2	P54278	896
MUTYH	MSH2	P43246	892
MUTYH	RAD9A	Q99638	891
MUTYH	APEX1	P27695	870
MUTYH	POLD1	P28340	868
MUTYH	MLH3	P49751	863
MUTYH	NTHL1	P78549	862
MUTYH	HUS1	O60921	819
MUTYH	TDG	Q13569	815
MUTYH	PMS1	P54277	813
MUTYH	MSH3	P20585	810

IntAct

39 interactions, top by confidence:

A	B	Type	Score
MUTYH	AKT1	psi-mi:“MI:2364”(proximity)	0.470
MUTYH	AKT1	psi-mi:“MI:0915”(physical association)	0.470
MUTYH	APEX1	psi-mi:“MI:0407”(direct interaction)	0.440
MUTYH	POLL	psi-mi:“MI:0407”(direct interaction)	0.440
MUTYH	MSH2	psi-mi:“MI:0407”(direct interaction)	0.440
BAAT	MUTYH	psi-mi:“MI:0915”(physical association)	0.370
MSANTD3	MUTYH	psi-mi:“MI:0915”(physical association)	0.370
MUTYH	TSTD2	psi-mi:“MI:0915”(physical association)	0.370
MUTYH	CYLC2	psi-mi:“MI:0915”(physical association)	0.370
FANCC	MUTYH	psi-mi:“MI:0915”(physical association)	0.370
HRAS	MUTYH	psi-mi:“MI:0915”(physical association)	0.370
MUTYH	SEC61B	psi-mi:“MI:0915”(physical association)	0.370
MUTYH	SMAD1	psi-mi:“MI:0915”(physical association)	0.370
TDRD7	MUTYH	psi-mi:“MI:0915”(physical association)	0.370
MUTYH	XPA	psi-mi:“MI:0915”(physical association)	0.370
NME4	PMPCB	psi-mi:“MI:0914”(association)	0.350
NME4	NDUFAB1	psi-mi:“MI:0914”(association)	0.350
FBXW7	MUTYH	psi-mi:“MI:2364”(proximity)	0.270
SMAD4	MUTYH	psi-mi:“MI:2364”(proximity)	0.270
MUTYH	SMARCA4	psi-mi:“MI:2364”(proximity)	0.270
SMARCA4	MUTYH	psi-mi:“MI:2364”(proximity)	0.270
SPOP	MUTYH	psi-mi:“MI:2364”(proximity)	0.270
MUTYH	SPOP	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (50): AGTRAP (Two-hybrid), MUTYH (Affinity Capture-MS), MUTYH (Affinity Capture-MS), MUTYH (Two-hybrid), SIRT6 (Affinity Capture-Western), MUTYH (Affinity Capture-Western), Sirt6 (Reconstituted Complex), SIRT6 (Reconstituted Complex), RAD9A (Co-localization), RAD9A (Affinity Capture-Western), RAD9A (Reconstituted Complex), MUTYH (Affinity Capture-Western), MUTYH (Affinity Capture-Western), MUTYH (Affinity Capture-Western), MUTYH (Affinity Capture-Western)

ESM2 similar proteins: A0A1D6LAG9, A2RTX5, A6QLY4, A6QNM8, A7M7B9, A9S0B8, A9VB27, B9DFZ0, C1BM18, E2RDZ6, F4JCQ3, G3X8U3, O35980, O70157, O75879, P13051, P36776, P54137, P78549, P97931, Q09907, Q0V9S0, Q13472, Q2KID2, Q4KM92, Q4R380, Q59HJ6, Q5ZKD7, Q640B4, Q7SXA9, Q80UN9, Q80VY9, Q8BLY2, Q8BYM8, Q8CGK3, Q8K582, Q8R5G2, Q8SRB8, Q924S5, Q99JT1

Diamond homologs: A0R567, F4JRF4, O31584, P17802, P39788, P44320, P46230, P57617, P73715, P83847, P9WQ08, P9WQ09, Q05869, Q10159, Q58030, Q7LX22, Q89A45, Q8R5G2, Q99P21, Q9UIF7, Q9YDP0, Q8K926, Q9SIC4, B9DFZ0, P57219, P0AB83, P0AB84, P29588, P44319, Q9WYK0, Q89AW4, Q8KA16, P46303, Q4UK93, P54137, C8VC05, O83754, Q08214, Q0IGK1, Q9Z2D7

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
MUTYH	up-regulates	ATR	binding
MUTYH	up-regulates	CHEK1
MUTYH	up-regulates	TOPBP1	binding
MUTYH	up-regulates	Base-excision_repair

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 27 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of miRNA transcription	5	58.1×	1e-05
positive regulation of ERK1 and ERK2 cascade	5	17.0×	1e-03
DNA repair	5	12.8×	3e-03
negative regulation of cell population proliferation	5	8.4×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

4186 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	184
Likely pathogenic	150
Uncertain significance	1900
Likely benign	1038
Benign	108

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1045946	NM_001048174.2(MUTYH):c.764_772del (p.Met255_Gly258delinsArg)	Pathogenic
1050536	NM_001048174.2(MUTYH):c.1393-51_*2del	Pathogenic
1068517	NM_001048174.2(MUTYH):c.811C>T (p.Gln271Ter)	Pathogenic
1069525	NM_001048174.2(MUTYH):c.775dup (p.Ala259fs)	Pathogenic
1070115	NM_001048174.2(MUTYH):c.507del (p.Gly171fs)	Pathogenic
1070581	NM_001048174.2(MUTYH):c.148C>T (p.Gln50Ter)	Pathogenic
1072128	NM_001048174.2(MUTYH):c.1425del (p.Thr476fs)	Pathogenic
1075894	NM_001048174.2(MUTYH):c.310dup (p.Val104fs)	Pathogenic
1076845	NM_001048174.2(MUTYH):c.376_377del (p.Gln126fs)	Pathogenic
127835	NM_001048174.2(MUTYH):c.928C>T (p.Gln310Ter)	Pathogenic
1352487	NM_001048174.2(MUTYH):c.409del (p.Ala137fs)	Pathogenic
1356072	NM_001128425.2(MUTYH):c.177_178insCA (p.Glu60fs)	Pathogenic
1364709	NM_001048174.2(MUTYH):c.924_925del (p.Gly309fs)	Pathogenic
1368442	NM_001048174.2(MUTYH):c.541C>T (p.Gln181Ter)	Pathogenic
1374111	NM_001048174.2(MUTYH):c.779_780del (p.Thr260fs)	Pathogenic
1395788	NM_001048174.2(MUTYH):c.136del (p.Glu46fs)	Pathogenic
1408238	NM_001048174.2(MUTYH):c.1276C>T (p.Gln426Ter)	Pathogenic
140827	NM_001048174.2(MUTYH):c.205C>T (p.Arg69Ter)	Pathogenic
140876	NM_001048174.2(MUTYH):c.856C>T (p.Gln286Ter)	Pathogenic
141379	NM_001048174.2(MUTYH):c.49del (p.Ala17fs)	Pathogenic
142604	NM_001048174.2(MUTYH):c.1130C>T (p.Pro377Leu)	Pathogenic
143003	NM_001048174.2(MUTYH):c.655C>T (p.Arg219Ter)	Pathogenic
1436665	NM_001048174.2(MUTYH):c.300T>A (p.Tyr100Ter)	Pathogenic
1441468	NM_001048174.2(MUTYH):c.685del (p.Val230fs)	Pathogenic
1452003	NM_001048174.2(MUTYH):c.1160_1167dup (p.Lys390fs)	Pathogenic
1454604	NM_001048174.2(MUTYH):c.1185del (p.Glu395fs)	Pathogenic
1455088	NM_001048174.2(MUTYH):c.228C>G (p.Tyr76Ter)	Pathogenic
1455631	NM_001048174.2(MUTYH):c.684_702dup (p.Trp235fs)	Pathogenic
1459595	NM_001048174.2(MUTYH):c.627del (p.Asn210fs)	Pathogenic
156509	NM_001048174.2(MUTYH):c.1087C>T (p.Gln363Ter)	Pathogenic

SpliceAI

2163 predictions. Top by Δscore:

Variant	Effect	Δscore
1:45329437:CCTG:C	acceptor_gain	1.0000
1:45331222:T:TA	donor_gain	1.0000
1:45331416:TTA:T	donor_loss	1.0000
1:45331417:TACCT:T	donor_loss	1.0000
1:45331418:A:AC	donor_gain	1.0000
1:45331418:AC:A	donor_gain	1.0000
1:45331418:ACCT:A	donor_gain	1.0000
1:45331418:ACCTC:A	donor_gain	1.0000
1:45331419:C:CT	donor_gain	1.0000
1:45331419:CC:C	donor_gain	1.0000
1:45331419:CCT:C	donor_gain	1.0000
1:45331419:CCTC:C	donor_gain	1.0000
1:45331419:CCTCC:C	donor_gain	1.0000
1:45331552:CAGAC:C	acceptor_gain	1.0000
1:45331553:AGAC:A	acceptor_gain	1.0000
1:45331554:GAC:G	acceptor_gain	1.0000
1:45331555:AC:A	acceptor_gain	1.0000
1:45331556:CC:C	acceptor_gain	1.0000
1:45331557:C:CC	acceptor_gain	1.0000
1:45332164:A:AC	donor_gain	1.0000
1:45332165:C:CC	donor_gain	1.0000
1:45332165:CT:C	donor_gain	1.0000
1:45332165:CTCT:C	donor_gain	1.0000
1:45332168:T:A	donor_gain	1.0000
1:45332246:G:C	donor_gain	1.0000
1:45332308:CCC:C	acceptor_gain	1.0000
1:45332309:CC:C	acceptor_gain	1.0000
1:45332309:CCC:C	acceptor_gain	1.0000
1:45332310:CC:C	acceptor_gain	1.0000
1:45332758:CTTA:C	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000047665 (1:45336022 A>G), RS1000260695 (1:45329414 G>A), RS1000609513 (1:45331010 G>A), RS1000623040 (1:45330159 G>C), RS1001144609 (1:45339009 C>T), RS1001379309 (1:45334630 A>C), RS1001390252 (1:45330624 C>T), RS1001416500 (1:45330397 C>T), RS1001667829 (1:45336118 C>T), RS1002437652 (1:45332754 T>C), RS1002637086 (1:45342032 G>A), RS1002936745 (1:45337865 G>T), RS1002995018 (1:45342425 G>A,C), RS1003048107 (1:45336349 C>T), RS1003275266 (1:45338190 T>C)

Disease associations

OMIM: gene MIM:604933 | disease phenotypes: MIM:608456, MIM:613659, MIM:132600, MIM:175100, MIM:114500, MIM:614969, MIM:120435, MIM:114480, MIM:167000, MIM:607259, MIM:155255, MIM:608089

GenCC curated gene-disease

Disease	Classification	Inheritance
familial adenomatous polyposis 2	Definitive	Autosomal recessive

ClinGen Gene-Disease Validity (6)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
familial ovarian cancer	Disputed	AR
familial ovarian cancer	Disputed	AD
familial adenomatous polyposis 2	Definitive	AR
hereditary breast carcinoma	Disputed	AR
colorectal cancer	Disputed	AD
hereditary breast carcinoma	Refuted	AD

Mondo (36): familial adenomatous polyposis 2 (MONDO:0012041), hereditary neoplastic syndrome (MONDO:0015356), gastric cancer (MONDO:0001056), colon carcinoma (MONDO:0002032), hereditary breast ovarian cancer syndrome (MONDO:0003582), breast carcinoma (MONDO:0004989), polyp of large intestine (MONDO:0021392), medulloblastoma SHH activated and TP53 wild-type (MONDO:0956965), pilomatrixoma (MONDO:0007564), gastric neoplasm (MONDO:0021085), familial adenomatous polyposis 1 (MONDO:0021056), diffuse midline glioma, H3 K27-altered (MONDO:1060171), hepatoblastoma (MONDO:0018666), colorectal cancer (MONDO:0005575), familial colorectal cancer (MONDO:0023113)

Orphanet (21): Attenuated familial adenomatous polyposis (Orphanet:220460), MUTYH-related polyposis (Orphanet:247798), Inherited cancer-predisposing syndrome (Orphanet:140162), Hereditary breast and/or ovarian cancer syndrome (Orphanet:145), Pilomatrixoma (Orphanet:91414), Hepatoblastoma (Orphanet:449), Pontocerebellar hypoplasia type 7 (Orphanet:284339), Familial colorectal cancer Type X (Orphanet:440437), Retinoblastoma (Orphanet:790), Lynch syndrome (Orphanet:144), Hereditary breast cancer (Orphanet:227535), Rare ovarian cancer (Orphanet:213500), Familial adenomatous polyposis (Orphanet:733), Spastic paraplegia type 7 (Orphanet:99013), Anaplastic/large cell medulloblastoma (Orphanet:251855)

HPO phenotypes

64 total (30 of 64 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000505	Visual impairment
HP:0000708	Atypical behavior
HP:0000716	Depression
HP:0000737	Irritability
HP:0000738	Hallucinations
HP:0000739	Anxiety
HP:0001123	Visual field defect
HP:0001250	Seizure
HP:0001252	Hypotonia
HP:0001260	Dysarthria
HP:0001276	Hypertonia
HP:0001288	Gait disturbance
HP:0001371	Flexion contracture
HP:0001402	Hepatocellular carcinoma
HP:0001442	Typified by somatic mosaicism
HP:0001824	Weight loss
HP:0002017	Nausea and vomiting
HP:0002019	Constipation
HP:0002024	Malabsorption
HP:0002027	Abdominal pain
HP:0002076	Migraine
HP:0002167	Abnormal speech pattern
HP:0002239	Gastrointestinal hemorrhage
HP:0002354	Memory impairment
HP:0002376	Developmental regression
HP:0002516	Increased intracranial pressure
HP:0002671	Basal cell carcinoma
HP:0002893	Pituitary adenoma
HP:0002894	Neoplasm of the pancreas

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST008573_5	Composite immunoglobulin trait (IgA/IgM)	1.000000e-08
GCST010726_80	Periventricular white matter hyperintensities	4.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005665	white matter hyperintensity measurement

MeSH disease descriptors (14)

Descriptor	Name	Tree numbers
D003110	Colonic Neoplasms	C04.588.274.476.411.307.180; C06.301.371.411.307.180; C06.405.249.411.307.180; C06.405.469.158.356.180; C06.405.469.491.307.180
D004806	Ependymoma	C04.557.465.625.600.380.290; C04.557.470.670.380.290; C04.557.580.625.600.380.290
D018197	Hepatoblastoma	C04.557.435.380
D061325	Hereditary Breast and Ovarian Cancer Syndrome	C04.588.180.483; C04.588.322.455.431; C04.700.517; C12.050.351.500.056.630.705.431; C12.050.351.937.418.685.431; C12.100.250.056.630.705.431; C12.900.418.685.431; C16.320.700.517; C17.800.090.500.483; C19.344.410.431; C19.391.630.705.431
D008527	Medulloblastoma	C04.557.465.625.600.380.515; C04.557.465.625.600.590.500; C04.557.470.670.380.515; C04.557.470.670.590.500; C04.557.580.625.600.380.515; C04.557.580.625.600.590.500
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
D010051	Ovarian Neoplasms	C04.588.322.455; C12.050.351.500.056.630.705; C12.050.351.937.418.685; C12.100.250.056.630.705; C12.900.418.685; C19.344.410; C19.391.630.705
D018296	Pilomatrixoma	C04.557.470.565.625
D012175	Retinoblastoma	C04.557.465.625.600.725; C04.557.470.670.725; C04.557.580.625.600.725; C04.588.364.818.760; C11.270.862; C11.319.475.760; C11.768.717.760
D013274	Stomach Neoplasms	C04.588.274.476.767; C06.301.371.767; C06.405.249.767; C06.405.748.789
C562840	Breast Cancer, Familial (supp.)
C563924	Colorectal Adenomatous Polyposis, Autosomal Recessive (supp.)
C537261	Lynch syndrome I (site-specific colonic cancer) (supp.)
C564599	Spastic Paraplegia 7, Autosomal Recessive (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5723574 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

2 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs3219484	Toxicity	3	cisplatin;cyclophosphamide	Ovarian Neoplasms
rs3219489	Efficacy	3	cisplatin;fluorouracil;radiotherapy	Carcinoma;Squamous Cell;Progression-free survival

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3219484	MUTYH	3	3.00	1	cisplatin;cyclophosphamide
rs3219489	MUTYH	3	3.75	1	cisplatin;fluorouracil;radiotherapy

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Particulate Matter	affects cotreatment, decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
bisphenol F	decreases expression	1
myristicin	decreases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
pirinixic acid	increases expression, affects binding, increases activity	1
beta-lapachone	increases expression	1
cobaltous chloride	decreases expression	1
potassium bromate	decreases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
pinostrobin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Bortezomib	decreases expression	1
Arsenic Trioxide	affects activity	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Ethanol	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Carbon Tetrachloride	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5665446	Functional	Inhibition of MUTYH by quantifying inhibition of MUTYH-mediated cleavage and dissociation of quenched duplex DNA oligonucleotides, measured as fluorescence at 594 nm. To generate a functional strand incision and increase turn-over this assa	Enzyme Inhibitor Single Concentration assay results for EUbOPEN Chemogenomics Library

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1TT	JIL-2266	Cancer cell line	Female
CVCL_B6PT	Jacket	Cancer cell line	Male
CVCL_E0IJ	Ubigene HeLa MUTYH KO	Cancer cell line	Female
CVCL_SZ48	HAP1 MUTYH (-) 1	Cancer cell line	Male
CVCL_SZ49	HAP1 MUTYH (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00365508	PHASE4	COMPLETED	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00558155	PHASE4	COMPLETED	The Impact of Immunostimulating Nutrition on the Outcome of Surgery
NCT00576940	PHASE4	COMPLETED	Standard and Immunostimulating Enteral Nutrition in Surgical Patients
NCT00666978	PHASE4	COMPLETED	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT01038154	PHASE4	UNKNOWN	Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
NCT01234272	PHASE4	COMPLETED	Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-
NCT01260194	PHASE4	TERMINATED	A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
NCT01271582	PHASE4	UNKNOWN	Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01401075	PHASE4	COMPLETED	RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients
NCT01471756	PHASE4	COMPLETED	Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
NCT01766765	PHASE4	UNKNOWN	Early Jejunostomy Nutrition Minimizes Time to Chemotherapy
NCT01910948	PHASE4	UNKNOWN	Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients
NCT01927328	PHASE4	UNKNOWN	Iron Replacement in Oesophagogastric Neoplasia
NCT01962272	PHASE4	COMPLETED	The Effect of Nutritional Counseling for Cancer Patients
NCT01962376	PHASE4	UNKNOWN	Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis
NCT02047994	PHASE4	RECRUITING	Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
NCT02235246	PHASE4	COMPLETED	The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study
NCT02366819	PHASE4	SUSPENDED	Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
NCT02401971	PHASE4	UNKNOWN	Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
NCT02458573	PHASE4	COMPLETED	Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy
NCT02638584	PHASE4	COMPLETED	Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.
NCT02776527	PHASE4	UNKNOWN	A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03550482	PHASE4	COMPLETED	Oncoxin® and Quality of Life in Cancer Patients
NCT03609892	PHASE4	COMPLETED	Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
NCT03642093	PHASE4	UNKNOWN	HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery
NCT03733639	PHASE4	UNKNOWN	Tisseel® as a Reinforcement of Esophagojejunal Anastomoses
NCT04168346	PHASE4	NOT_YET_RECRUITING	Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer
NCT04209933	PHASE4	COMPLETED	Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies
NCT04591028	PHASE4	WITHDRAWN	A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients
NCT04607057	PHASE4	UNKNOWN	Supplemental Parenteral Nutrition During Postgastrectomy in Nutritionally at Risk Patient
NCT04660123	PHASE4	COMPLETED	A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
NCT04678492	PHASE4	COMPLETED	Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT04697186	PHASE4	COMPLETED	Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
NCT05029453	PHASE4	UNKNOWN	Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
NCT05183126	PHASE4	RECRUITING	Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT05354856	PHASE4	TERMINATED	The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.
NCT05410535	PHASE4	COMPLETED	To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy
NCT05498766	PHASE4	NOT_YET_RECRUITING	Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
NCT05518929	PHASE4	COMPLETED	Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients